Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 11-14 results of 14
Lung Cancer

NRG-LU008

Official Title: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer 
Study Purpose: To compare overall survival in patients with Stage II-IIIC inoperable Non-small cell lung cancer comparing conventional radiation with chemotherapy  to stereotactic body radiation and conventional  radiation along with chemotherapy
Status: Recruiting
Lung Cancer

S1914

Official Title: A randomized Phase III Trial of Induction/consolidation Atezolizumab (NSC #783608) + SBRT Alone in High Risk, Early Stage NSCL
Study Purpose: To compare overall survival in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab
Status: Recruiting
Lung Cancer

S2302

Official Title: Non-chemotherapy treatment (Ramucirumab plus Pembrolizumab) or usual care for advanced non-small cell lung cancer following immunotherapy
Study Purpose: To compare overall survival in participants previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer randomized to Pembrolizumab and Ramucirumab versus standard of care. 
Status: Recruiting
Lung Cancer

XmAb717-06

Official Title: Aphase 1b/2 Open Label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab In Combination With Chemotherapy as First Line Treatment In Patients with Advanced Non-Small Lung Cancer 
Study Purpose: To find a safe, tolerable, and recommended dose of vudalimab for people with locally advanced (unresectable) or metastatic NSCL when combine with chemotherapy.
Status: Recruiting